Discussion
Preventive treatment with Hemlibra (emicizumab-kxwh) kept bleeding under control for nearly three years in people with mild or moderate hemophilia A without inhibitors. That’s according to long-term data from the Phase 3 HAVEN 6 trial (NCT04158648). The results build on earlier findings showing that Hemlibra effectively controlled…